Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58718) - R7 - Effective June 25, 2026

Date Posted: June 25, 2026

This Billing and Coding Article has been revised under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: May 11, 2026

Summary of Changes:

Under CPT/HCPCS Codes Group 1: Paragraph added "ExoDX Prostate assay (PLA 0005U), performed on non-DRE urine specimens". Under CPT/HCPCS Codes Group 1: Codes added 0005U. Under CPT/HCPCS Codes Group 2: Paragraph added "ExoDX Prostate assay (PLA 0005U), performed on non-DRE urine specimens". Under CPT/HCPCS Codes Group 2: Codes added 0005U. This revision is effective 5/11/2026.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Jun 25 , 2026